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Abstract
Fluoroquinolone antibiotics are among the most potent second-line drugs used for treatment of multidrug-resistant
tuberculosis (MDR TB), and resistance to this class of antibiotics is one criterion for defining extensively drug resistant
tuberculosis (XDR TB). Fluoroquinolone resistance in Mycobacterium tuberculosis has been associated with modification of
the quinolone resistance determining region (QRDR) of gyrA. Recent studies suggest that amino acid substitutions in gyrB
may also play a crucial role in resistance, but functional genetic studies of these mutations in M. tuberculosis are lacking. In
this study, we examined twenty six mutations in gyrase genes gyrA (seven) and gyrB (nineteen) to determine the clinical
relevance and role of these mutations in fluoroquinolone resistance. Transductants or clinical isolates harboring T80A,
T80A+A90G, A90G, G247S and A384V gyrA mutations were susceptible to all fluoroquinolones tested. The A74S mutation
conferred low-level resistance to moxifloxacin but susceptibility to ciprofloxacin, levofloxacin and ofloxacin, and the
A74S+D94G double mutation conferred cross resistance to all the fluoroquinolones tested. Functional genetic analysis and
structural modeling of gyrB suggest that M330I, V340L, R485C, D500A, D533A, A543T, A543V and T546M mutations are not
sufficient to confer resistance as determined by agar proportion. Only three mutations, N538D, E540V and R485C+T539N,
conferred resistance to all four fluoroquinolones in at least one genetic background. The D500H and D500N mutations
conferred resistance only to levofloxacin and ofloxacin while N538K and E540D consistently conferred resistance to
moxifloxacin only. Transductants and clinical isolates harboring T539N, T539P or N538T+T546M mutations exhibited low-
level resistance to moxifloxacin only but not consistently. These findings indicate that certain mutations in gyrB confer
fluoroquinolone resistance, but the level and pattern of resistance varies among the different mutations. The results from
this study provide support for the inclusion of the QRDR of gyrB in molecular assays used to detect fluoroquinolone
resistance in M. tuberculosis.
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Introduction
Mycobacterium tuberculosis is the etiologic agent of tuberculosis
(TB), a potentially fatal illness which results in approximately 2
million deaths worldwide each year [1]. TB treatment requires a
lengthy multi-drug regimen, and TB control efforts have been
hampered by the emergence of resistance to the first-line drugs. In
2008, approximately 440,000 new cases of TB in the world were
resistant to the two most effective first-line drugs, rifampicin and
isoniazid (multidrug-resistant TB, MDR TB) [2]. Treatment of
patients infected with a drug-resistant strain requires the use of
more toxic and less efficient drugs with a longer treatment period
as compared to drug-susceptible strains [3]. New, safer drugs are
desperately needed to combat the spread of drug resistant M.
tuberculosis.
The fluoroquinolone (FQ) antibiotics are widely used to treat
bacterial infections of the respiratory, gastrointestinal, and urinary
tract as well as sexually transmitted diseases and osteomylitis [4].
FQs also have excellent in vitro and in vivo activity against M.
tuberculosis and have proven to be among the most effective second-
line antimicrobial drugs used for the treatment of individuals
infected with MDR TB and patients experiencing severe adverse
effects due to first-line drugs [5,6]. FQs such as moxifloxacin are
also being evaluated for use as first-line drugs in treatment
protocols designed to shorten treatment duration of drug-
susceptible TB [7,8].
FQs belong to the quinolone class of antibiotics which inhibit
bacterial DNA gyrase and topoisomerase IV. DNA gyrase is an
ATP-dependent enzyme which cleaves and reseals double-
stranded DNA thereby introducing negative supercoils into
DNA. This activity is essential for DNA replication, transcription,
and recombination [9,10]. DNA gyrase consists of two GyrA and
two GyrB subunits encoded by gyrA and gyrB, respectively
[11,12,13]. Topoisomerase IV is also a heterodimer and consists
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Topoisomerase IV relaxes positive supercoils and decatenates
DNA following DNA replication allowing the two daughter
chromosomes to separate [10,12]. Many bacterial species possess
both DNA gyrase and topoisomerase IV. However, M. tuberculosis
lacks parC and parE homologs, and DNA gyrase appears to be the
sole target for FQ antibiotics [14].
Despite the potency of FQs in killing M. tuberculosis, resistant
strains have emerged. FQ resistance in M. tuberculosis is mainly due
to the acquisition of point mutations within the quinolone
resistance-determining region (QRDR) of gyrA with codons 90
and 94 being the most mutated sites [15,16,17]. Mutations in this
region account for 42–100% of FQ resistance in M. tuberculosis
[16,18,19,20]. Though FQ resistance due to gyrB mutations was
thought to be rare, clinical isolates resistant to FQs with gyrB
mutations and wild type (WT) gyrA loci were recently reported in
several studies [4,21,22,23,24,25,26,27,28]. Attempts to under-
stand the contributions of gyrA and gyrB mutations to FQ resistance
have often been carried out by in vitro enzymatic assays using
purified DNA gyrase [9,21,26,27]. Therefore, the true genetic
contributions of some gyrA and most gyrB mutations to M.
tuberculosis FQ resistance are not known. To date, functional
genetic studies of gyrA mutations that are outside the QRDR or
gyrB mutations in clean M. tuberculosis genetic backgrounds have
not been undertaken, and certain gyrA and gyrB mutations reported
to confer cross-resistance to different FQ antibiotics based on
clinical data have not yet been characterized in well-studied M.
tuberculosis backgrounds. As a result, the clinical significance of
these mutations in M. tuberculosis and FQ resistance is unknown.
We introduced several mutations identified within gyrA and gyrB
into M. tuberculosis laboratory strains and assessed their true
significance in FQ resistance. A better understanding of the
genetic basis of FQ resistance in M. tuberculosis is needed to help in
the development of molecular diagnostic tests to rapidly detect
drug resistance to ensure TB patients receive a correct treatment
regimen.
Materials and Methods
Bacterial Strains and Culture Conditions
Plasmids, cosmids and phages used in this study are described in
Table S1. Escherichia coli DH5a (Zymo Research) and HB101
(Invitrogen) were grown in Luria-Bertani (LB) broth or on LB agar
plates at 37uC. Mycobacterium smegmatis LR222 [29] and M.
tuberculosis liquid cultures were grown at 37uC in Middlebrook
7H9 broth supplemented with 10% (vol/vol) albumin-dextrose-
catalase (ADC) enrichment (BD Bioscience) and 0.05% (vol/vol)
Tween 80 (Sigma). Middlebrook 7H10 agar supplemented with
10% (vol/vol) oleic acid-ADC (OADC) enrichment (BD Biosci-
ence) was used for growing M. tuberculosis on solid medium at 37uC.
When required, hygromycin B (Invitrogen) was added to growth
medium at a final concentration of 150 mg/mL for E. coli and
75 mg/mL for M. tuberculosis.
Clinical Isolates
Clinical isolates used in this study (Table 1) were selected from
the culture collection of the Laboratory Branch, Division of
Tuberculosis Elimination, U.S. Centers for Disease Control and
Prevention. These strains had previously been tested for suscep-
tibility to first and select second line drugs using standard
procedures (Table S3). FQ susceptibility testing, DNA isolation
and sequencing of gyrA QRDR was carried out according to
methods previously described [15]. In addition, the promoter
region and the entire open reading frame (ORF) of gyrA and gyrB of
clinical isolates used in this study were sequenced with primer sets
described in Table S2.
Construction of Recombinant Cosmids Containing Allelic
Exchange Substrates
Recombinant cosmids containing allelic exchange substrates
were constructed for generating point mutations in gyrA and gyrB
(Table S4). These mutations were introduced into M. tuberculosis
strains H37Rv and Erdman using the phage delivery system as
previously described [30,31,32].
Table 1. List of M. tuberculosis isolates used in this study.
Strain Background Mutation Range of MIC (mg/mL)
gyrA gyrB CIP OFX LVX MXF
MLB 135 Clinical isolate G247S – 0.5 1 ,0.25 ,0.25
MLB 5 Clinical isolate – V340L 1 1 0.5 ,0.25
MLB 105 Clinical isolate G247S D500N 2 420.5
MLB 159 Clinical isolate – D500H 2 841
MLB 175 Clinical isolate A384V M330I ,0.25 0.5 ,0.25 ,0.25
MLB 20 Clinical isolate A90V – 4421
MLB 263 Clinical isolate D94G – 8882
MLB 264 Clinical isolate – N538D+T546M 4421
MLB 265 Clinical isolate – N538T+T546M 2 0.5 0.5 ,0.25
MLB 259 Clinical isolate T80A – 0.5 0.5 ,0.25 ,0.25
MLB 261 Clinical isolate – R485C+T539N 1–2 4–82 2 –4
MLB 262 Clinical isolate – N538D 4421
H37Rv Laboratory strain – – 0.5 0.5 ,0.25 ,0.25–0.5
Erdman Laboratory strain – – 0.5 0.5 ,0.25 ,0.25–0.5
2, no mutation, CIP, ciprofloxacin, OFX, ofloxacin, LVX, levofloxacin, MXF, moxifloxacin. Resistance defined as; CIP (.2 mg/mL), OFX (.2 mg/mL), LVX (.1 mg/mL) and
MXF (.0.5 mg/mL). Highlighted in bold font are MICs considered resistant to that specific FQ.
doi:10.1371/journal.pone.0039754.t001
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DNA of H37Rv using Phusion high-fidelity DNA polymerase
(Finnzymes) and the primers gyrAUSF and gyrAUSR (Table S2).
The PCR conditions were 98uC for 2 min for denaturing followed
by 30 cycles of denaturation at 98uC for 10 sec, annealing at 57uC
for 5 sec, extension at 72uC for 45 sec and a final elongation at
72uC for 2 min. The resulting PCR fragment was cloned into
pCR-BluntII-TOPO (Invitrogen), yielding plasmid pSM630 (Ta-
ble S1). To construct plasmid pSM631, a 715 bp PCR fragment of
Rv0007, the gene immediately downstream of gyrA, was amplified
from the genomic DNA of H37Rv using primers gyrADSF and
gyrADSR (Table S2) and cloned into pCR-BluntII-TOPO. To
construct the recombinant gyrA wild-type cosmid pCSM649, the
2.7-kb KpnI/XbaI fragment from pSM630 was subcloned into the
corresponding restriction sites in pYUB854 [30] upstream of the
HYG cassette (Table S1). Furthermore, the 715 bp HindIII/SpeI
fragment from pSM631 containing Rv0007 was cloned into
HindIII/SpeI restriction sites of pCSM649 downstream of HYG
cassette to create cosmid pCSM650. The recombinant cosmids
pCSM670, pCSM673, pCSM674, pCSM675 and pCSM676
(Table S1) were constructed in the same fashion except that
genomic DNA from clinical isolates MLB 259, MLB 20, MLB
263, MLB135 and MLB 175 respectively (Table 1) containing
various gyrA mutations were used for amplification of the 2.7-kb
gyrA fragments. Cloned sequences were verified by sequencing. For
analysis of gyrB sequences, a 2.2-kb fragment was amplified from
genomic DNA of H37Rv with primer set gyrBUSF and gyrBUSR
(Table S2) using the same PCR conditions as described previously
and then cloned into pCR-BluntII-TOPO (Invitrogen) to create
plasmid pSM632 (Table S1). In addition, an 830 bp gyrA PCR
fragment was amplified from H37Rv genomic DNA using primer
set gyrBDSF and gyrBDSR (Table S2). The resulting PCR
product was cloned into pCR-BluntII-TOPO to yield plasmid
pSM633. The recombinant gyrB wild-type cosmid was created by
subcloning a 2.2-kb KpnI/XbaI fragment from pSM632 into the
upstream region of HYG cassette in the corresponding restriction
sites in pYUB854 resulting in cosmid pCSM651. The 830 bp
HindIII/SpeI fragment cut out from pSM633 (Table S1) was
inserted into the corresponding restriction sites downstream of the
HYG cassette to create cosmid pCSM652. The recombinant
cosmids containing gyrB point mutations that were present in
clinical isolates of our culture collection were created in the same
way as pCSM652 except that, the 2.2-kb fragment for each cosmid
was amplified from genomic DNA of clinical isolates as described
in Table 1.
Site-directed Mutagenesis
Cosmids containing points mutations not found in our culture
collection of clinical isolates were generated using the Quick-
Change Lightening site-directed mutagenesis kit (Agilent) with
wild-type cosmid pCSM650 (gyrA) or pCSM652 (gyrB) (Table S1)
serving as template and appropriate mutagenic primers described
in Table S2. Cosmid pCSM669 containing the double gyrA
mutation (A74S+D94G) was created using the QuickChange
method to insert the A74S mutation into cosmid pCSM674
(D94G). Cosmid pCSM671 (T80A+A90G) was created using a
similar approach but with cosmid pCSM670 (T80A) as template.
All the constructs were verified by DNA sequencing.
Construction of Specialized Transducing
Mycobacteriophages
The specialized transducing mycobacteriophage used in this
study were constructed as previously described [30,31,32]. Briefly,
the recombinant cosmids (Table S1) were digested with PacI and
ligated with phAE159 shuttle phasmid DNA linearized with PacI
to generate phasmids. The recombinant phasmids were packaged
into phage heads using a l in vitro packaging extract kit (Gigapack
III XL, Agilent) and transduced into E. coli HB101. Transductants
were selected on LB plates containing HYG. Phasmid DNA was
isolated from E. coli HB101 and electroporated into M. smegmatis
LR222. The resulting transducing phages were plaque purified
and amplified to obtained high titer phage lysate. The presence of
allelic exchange substrates was confirmed by PCR and DNA
sequencing.
Transduction of M. tuberculosis for the Introduction of
Allelic Exchange Substrates
M. tuberculosis strains were transduced with high titer phage
lysates as previously described [31,32]. Transductants were
selected on Middlebrook 7H10 plates containing HYG and
incubated at 37uC for 4 weeks. Point mutations in gyrA were
verified by PCR and sequencing with primer sets gyrA1F and
gyrA1R (Table S2). Two sets of primers were used for gyrB point
mutations; M330I and V340L were confirmed with primer set
gyrB2F and gyrB2R (Table S2), while all other gyrB transductants
were validated with primer set gyrBSF and gyrBSR (Table S2).
The presence of HYG cassette in all the transductants was
confirmed by PCR using Hyg-US and Hyg-DS primers (Table
S2).
Structural Modeling of the M. tuberculosis Gyrase-DNA-
quinolone Complex
Crystal structures of the N-terminal domain of M. tuberculosis
GyrA (PDB ID: 3IFZ) [33] and the C-terminal domain of M.
tuberculosis GyrB (PDB ID: 3M4I) [33] were superimposed onto the
respective highly homologous regions in the crystal structure of the
complex of Streptococcus pneumoniae gyrase with a DNA substrate and
levofloxacin (PDB ID: 3K9F) [34] by using the SSM superposition
tool in Coot [35]. A few minor steric clashes that arose were
avoided by minor adjustments of side chain torsion angles. Two
residues (R485 and S486) were added to the N-terminus of the C-
terminal domain of GyrB in the extended conformation of the
backbone to illustrate that R485 is located in the interface with
GyrA. This specific backbone conformation is arbitrary, as R485
would be located in the interface with GyrA for any chemically
allowed conformation due to the close proximity of the N-terminus
of the C-terminal domain of GyrB to this interface.
Determination of Minimum Inhibitory Concentrations
(MICs)
The MICs for ciprofloxacin (CIP) (Sigma), levofloxacin (LVX)
(Sigma), moxifloxacin (MXF) (U. S. Pharmacopeia) and ofloxacin
(OFX) (Sigma) for M. tuberculosis isolates were determined using the
agar proportion method as previously described [36]. Clinical
strains and transductants were grown on 7H10 agar plates with
OADC enrichment containing the following drug concentrations
for CIP, LVX, OFX, and MXF: 0.25, 0.5, 1, 2, 4, 8 and 16 mg/
mL. Plates were incubated at 37uC and read at 21 and 28 days.
The MIC was defined as the minimum concentration of drug
which resulted in growth in the drug quadrant that was ,1% of
that in the no drug quadrant. Resistance to CIP and OFX was
defined as MIC .2 mg/mL, LVX, MIC .1 mg/mL, MXF, MIC
.0.5 mg/mL (low level resistance) and MIC .2 mg/mL (high
level resistance). MIC determinations were done in biological
duplicate for each clinical isolate and transductant used in this
study to ensure reproducibility.
Fluoroquinolone Resistance in M. tuberculosis
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The Significance of gyrA Mutations and FQ Resistance
In order to ensure that the MIC observed with clinical isolates
harboring mutations in gyrA or gyrB is directly related to those
specific mutations, we introduced single or double mutations into
the well-characterized M. tuberculosis strains H37Rv and Erdman
using the mycobacteriophage allelic exchange system and deter-
mined the MIC for CIP, LVX, MXF and OFX. Strains were only
considered to be resistant if the MIC for a particular FQ was
greater than the recommended critical concentration for the agar
proportion method using 7H10 medium [36]. These critical
concentration values are 2 mg/ml for CIP and OFX, 1.0 mg/ml
for LVX, and 0.5 and 2 mg/ml for MXF. Two concentrations
were used for MXF to allow us to discriminate between low and
high-level resistant strains.
A potential problem with the phage system is the insertion of the
hygromycin (HYG) resistance cassette into the chromosome in
order to select for the transductants. In this case, the HYG cassette
was introduced between the gyrA and gyrB genes for all
transductants. We transduced both H37Rv and Erdman with
mycobacteriophage carrying either wild-type gyrA/gyrB (A1, A2
and B1, B2) or the gyrA A90V (A10 and A11) mutation to ensure
that the introduction of the HYG cassette did not affect the MIC
for the FQs tested in this study. The MIC for CIP, LVX, MXF
and OFX of all wild-type transductants was 0.5, ,0.25, ,0.25
and 0.5 mg/mL (Table 2 and 3), respectively, and these results
were similar to the parental strains, H37Rv and Erdman (Table 1).
The MIC of transductants carrying the A90V (A10 and A11) allele
were also similar to that of a clinical isolate (MLB20) harboring
this same mutation (Tables 1 and 2). Based on these results, the
phage system is applicable for functional genetic studies of these
genes since the introduction of the HYG resistance cassette
between the gyrA and gyrB genes did not influence the MIC of the
strains.
By using this system, we analyzed recently reported mutations
(A74S and T80A + A90G) [21,37] located within the gyrA QRDR
and two novel mutations identified in this study (G247S and
A384V) that are located outside of the QRDR of gyrA. The
Table 2. MIC of gyrA transductants/mutants.
Strain Background Mutation Range of MIC (mg/mL)
CIP OFX LVX MXF
A1 H37Rv WT ,0.25–0.5 0.5 ,0.25 ,0.25
A2 Erdman WT ,0.25–0.5 0.5 ,0.25 ,0.25
A3 Erdman A74S 1 1–2 1 0.5–1
A4 H37Rv A74S+D94G 16 16–32 16 4–16
A5 H37Rv T80A 0.5 ,0.25 ,0.25 ,0.25
A6 Erdman T80A 0.5 0.5 ,0.25 ,0.25
A7 H37Rv T80A+A90G ,0.25 ,0.25 ,0.25 ,0.25
A8 Erdman T80A+A90G ,0.25 ,0.25 ,0.25 ,0.25
A9 Erdman A90G ,0.25 ,0.25 ,0.25 ,0.25
A10 H37Rv A90V 2–4 2–4 0.5–2 0.5–1
A11 Erdman A90V 4 2–8 0.5–4 0.5–1
A12 CDC1551 D94G 88 8 2
A13 H37Rv G247S ,0.25 0.5 ,0.25 ,0.25
A14 Erdman G247S 0.5 0.5 ,0.25 ,0.25
A15 H37Rv A384V 0.5 1 0.5 ,0.25
A16 Erdman A384V 1 1 0.5 ,0.25
WT, wild type. Resistance defined as; CIP (.2 mg/mL), OFX (.2 mg/mL), LVX
(.1 mg/mL) and MXF (.0.5 mg/mL). Highlighted in bold font are MICs
considered resistant to that specific FQ.
doi:10.1371/journal.pone.0039754.t002
Table 3. MIC of gyrB transductants/mutants.
Strain
Back-
ground Mutation Range of MIC (mg/mL)
CIP OFX LVX MXF
B1 H37Rv WT ,0.25–0.5 0.5 ,0.25 ,0.25–0.5
B2 Erdman WT ,0.25–0.5 0.5 ,0.25 ,0.25–0.5
B3 Erdman M330I ,0.25 0.5 ,0.25 ,0.25
B4 H37Rv V340L 0.5 0.5 ,0.25 ,0.25
B5 Erdman V340L 0.5 1 0.5 ,0.25
B6 H37Rv R485C 1 1 1 ,0.25
B7 Erdman R485C 1 1 1 ,0.25–0.5
B10 H37Rv D500A 0.5 2 1 ,0.25–0.5
B11 Erdman D500A 0.5 2 1 ,0.25–0.5
B16 H37Rv D533A ,0.25 0.5 ,0.25 ,0.25
B17 Erdman D533A 0.5 1 ,0.25 ,0.25
B34 H37Rv A543T 1 0.5–2 1 ,0.25–0.5
B35 Erdman A543T 1 1 1 ,0.25–0.5
B36 H37Rv A543V 0.5–1 1 0.5–1 0.5
B37 Erdman A543V 1 2 1 0.5–1
B38 H37Rv T546M ,0.25 0.5 ,0.25 ,0.25
B39 Erdman T546M ,0.25 0.5 ,0.25 ,0.25
B26 H37Rv T539N 1 2 1 ,0.25–0.5
B27 Erdman T539N 2 2 1 1
B28 H37Rv T539P 1 0.5–1 0.5–1 0.5–1
B29 Erdman T539P 1 0.5–1 0.5–1 0.5–1
B24 H37Rv N538T+T546M 2 0.5 0.5 0.5–1
B25 Erdman N538T+T546M 2 0.5 0.5 ,0.25–1
B30 H37Rv E540D 0.5 0.5 0.5 2–4
B31 Erdman E540D 0.5–1 0.5–1 0.5 2
B22 H37Rv N538K 2 2 1 1–2
B23 Erdman N538K 2 2 1 1–2
B12 H37Rv D500H 1–2 4–82 –4 ,0.25–0.5
B13 Erdman D500H 1 4–82 –4 0.5
B14 H37Rv D500N 1 42,0.25–0.5
B15 Erdman D500N 2 420.5
B32 H37Rv E540V 2 4 1–2 0.5–1
B33 Erdman E540V 2–44 2 1
B8 H37Rv R485C+T539N 2 4–82 –42
B9 Erdman R485C+T539N 48 4 4
B18 H37Rv N538D 44 2 1
B19 Erdman N538D 44 2 1
B20 H37Rv N538D+T546M 4 2 21
B21 Erdman N538D+T546M 84 2 1 –2
WT, wild type. Resistance defined as; CIP (.2 mg/mL), OFX (.2 mg/mL), LVX
(.1 mg/mL) and MXF (.0.5 mg/mL). Highlighted in bold font are MICs
considered resistant to that specific FQ.
doi:10.1371/journal.pone.0039754.t003
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and A16) exhibited similar MICs as compared to the negative
control strains (A1 and A2) and did not confer resistance to any of
the FQs tested (Table 2). These results were also similar for clinical
isolates containing either G247S or A384V gyrA mutations.
However, clinical isolate MLB105 which contains a mutation in
gyrA (G247S) and gyrB (D500N) exhibited a higher MIC for all FQs
tested (Table 1). The gyrA double mutation T80A +A90G (A7 and
A8) also had no significant effect on MICs and may actually
decrease the MIC for OFX. We also introduced these mutations
independently into H37Rv and/or Erdman (A5, A6 and A9) and
observed similar results as compared to the double mutation
(Table 2). In the case of T80A, the clinical isolate (MLB259)
harboring this mutation also has similar MICs.
The A74S mutation (A3) increased the MIC two to four fold for
each FQ tested. However, because these values are still below the
critical concentration commonly used to test M. tuberculosis, this
strain is considered susceptible to CIP, OFX, and LVX. This
strain exhibited low-level resistance to MXF (MIC of 1 mg/ml)
once and susceptible on the repeat test. The A74S mutation has
also been reported in combination with a D94G mutation [38].
The single D94G mutation does confer resistance in the clinical
isolate (MLB263) and transductant (A12), but the addition of A74S
to D94G (A4) further increased the MICs 2–8 fold over that of the
single D94G mutation for all FQs tested (Table 2). The
combination of A74S and D94G mutations in gyrA appears to
have a synergistic effect and elevate the MIC for FQs.
Clinical Relevance of M. tuberculosis gyrB Mutations and
FQ Resistance
The presence of gyrB mutations, especially at codon D500H and
D500N have previously been identified in laboratory strains of M.
tuberculosis exposed to FQ antibiotics to generate spontaneous FQ
resistant mutants [39]. FQ-resistant M. tuberculosis strains harbor-
ing gyrB mutations have been isolated recently from TB patients in
several parts of the world, albeit at low frequency
[4,21,22,23,24,25,26,27,28]. In order to gain better insight into
the effects of gyrB mutations, we performed functional genetic
studies and introduced 19 gyrB mutations into pansusceptible M.
tuberculosis and assessed their role in FQ resistance. At least three
different numbering systems based on the choice of the start codon
of M. tuberculosis gyrB have been used to report the amino acid
substitutions in gyrB [40]. In this paper, we used the ‘‘A’’
numbering system (Fig. 1) because our experimental design was
based on http://genolist.pasteur.fr/TubercuList/annotation. We
have also provided the alternative numbering systems in Figure 1
including the one recently proposed by Maruri et al [40].
The novel gyrB mutations M330I (B3), V340L (B4 and B5), and
T546M (B38 and B39) identified in this study did not confer
resistance to any of the FQs tested and exhibited MICs similar to
the control strains (B1 and B2) with wild-type gyrB (Table 3).
Transductants harboring the previously published D533A (B16
and B17) gyrB mutation [24] were also susceptible to all four FQs.
The T539P mutation was identified in an OFX-resistant strain
from Vietnam, in combination with an A90V gyrA mutation [22].
In a wild type gyrA background, the T539P (B28 and B29)
mutation alone did not substantially affect the MIC for any of the
FQs except LVX (up to 4 fold increase), but the increase of the
MIC for LVX was not sufficient to be considered resistant. The
A543T and A543V gyrB mutations identified in OFX-resistant M.
tuberculosis strains from Russia [25] were also included in this study.
Neither mutation had any effect on the MIC for MXF, but both
increased (2–4 fold) the MIC for the other three FQs. Once again,
the MICs were still below the critical concentration for this testing
method, and the transductants carrying these mutations (B34–37)
were considered susceptible to all FQs tested. Based on these data,
the M330I, V340L, D533A, T539P, T546M, A543T and A543V
mutations are not sufficient to confer resistance to the FQs tested.
The R485C and T539N gyrB mutations were reported
independently of each other in two studies. The T539N mutation
was associated with LVX resistance [28] while the R485C
mutation was associated with OFX resistance [23]. The level of
cross resistance among other FQs was not investigated in either
study. In the present study, these mutations slightly increased the
Figure 1. Amino acid substitutions in M. tuberculosis gyrB.A , numbering system according to http://genolist.pasteur.fr/TubercuList/
annotation, B, numbering system according to [45] C, numbering system according to http://tuberculist.epfl.ch/index.html annotation. Highlighted
in bold are the mutations we analyzed in this study.
doi:10.1371/journal.pone.0039754.g001
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introduced into H37Rv (B6 and B26) or Erdman (B7 and B27)
(Table 3). The T539N mutation did confer low-level resistance to
MXF in Erdman. Our results do not agree with the previous
reports [28,41], but in one study, the strains harboring either the
T539N or R485C mutation also contained the A90V gyrA
mutation that is known to confer resistance to FQs [41]. The
concentration of LVX used in the other study (1 mg/ml instead of
2 mg/ml) was below the critical concentration for LJ medium [28].
Although, we did not observe these mutations independently of
one another in any of our clinical isolates, we identified these
mutations together in a single extensively drug resistant (XDR)
isolate (MLB 261). This strain was resistant to OFX, LVX, and
MXF but susceptible to CIP (Table 1). When we introduced
R485C+T539N into H37Rv (B8), this double mutation conferred
resistance to OFX, LVX, and MXF, similar to clinical isolate
MLB 261 (Tables 1 and 3). However, the same double mutation in
the Erdman genetic background (B9) conferred resistance to all of
the FQs tested. Based on these results, the individual mutations
slightly increase the MIC for each FQ, however, in combination,
they act synergistically to increase the MIC above the critical
concentration used to test strains by agar proportion on 7H10
media.
Three different amino acid substitutions at codon 500 (D500A,
D500H and D500N) in gyrB have been reported in M. tuberculosis
[22,39,41]. In one study, the D500H mutation was identified in
CIP and OFX-resistant isolates, but the isolates also contained a
mutation in gyrA known to confer resistance to these FQs [39].
Duong et al., [22] reported clinical isolates harboring the D500N
or D500A mutation were resistant to OFX, but the one strain
harboring D500A also contained the A90V gyrA mutation. We
introduced each mutation that occurs at codon 500 into a wild
type gyrA background to determine if these mutations alone could
confer resistance. In this study, transductants harboring D500H
(B12 and B13) or D500N (B14 and B15) were resistant to LVX
and OFX but susceptible to CIP and MXF (Table 3). These results
are also similar for clinical isolates harboring either the D500H
(MLB159) or D500N (MLB105) gyrB mutation (Table 1). Trans-
ductants harboring the D500A (B10 and B11) gyrB mutation had
an increased MIC for LVX and OFX (at least 4 fold) while the
MIC for CIP and MXF was not affected. The transductants are
considered susceptible since the MIC is below the critical
concentration for each FQ tested. Based on these results, the
D500H and D500N mutations confer resistance to OFX and LVX
while the D500A mutation does not increase the MIC for any FQ
tested above the testing threshold.
Four different amino acid substitutions (N538D, N538K,
N538S and N538T) have been reported at codon 538 of gyrB in
M. tuberculosis [4,9,21,22,25]. The N538D mutation was reported
to confer cross-resistance to LVX, MXF and OFX (CIP not tested)
in a single clinical isolate, and the gyrase complex containing the
mutated gyrB was resistant to these FQs in an in vitro enzymatic
assay [21]. This mutation was associated with resistance to CIP,
MXF and OFX but susceptible to LVX in another study [4]. In
this study, transductants harboring the N538D (B18 and B19)
mutation exhibited cross-resistance to CIP, LVX, MXF and OFX
(Table 3). These results were the same for the clinical isolate MLB
262 which also harbors the N538D mutation (Table 1). In
addition, the N538K gyrB mutation was reported in an OFX-
resistant clinical M. tuberculosis strain from Russia, but this isolate
also harbored the D94G gyrA mutation that is known to confer FQ
resistance [25]. In this study, the N538K mutation (B22 and B23)
exhibited low-level resistance to MXF (MIC 1–2 mg/mL) and
increased the MIC level (4 fold) for CIP, OFX, and LVX.
However, this increase was not sufficient to be considered resistant
to these three FQs.
We also identified two novel double-mutations N538D+T546M
and N538T+T546M in clinical isolates MLB 264 and MLB 265,
respectively. We have shown in this study that T546M does not
confer FQ resistance, and the N538D mutation confers cross-
resistance to all the FQs tested. The N538D+T546M mutation
(B21) also conferred resistance to all of the FQs tested when
introduced into Erdman but did not significantly increase the MIC
more than N538D alone. Similar results were obtained for the
clinical strain MLB 264 (N538D+T546M) and MLB 262 (N538D)
(Table 1 and 3). However, the N538D+T546M double mutation
resulted in slightly different results in the H37Rv genetic
background (B20) where it was resistant to CIP, LVX and MXF
but consistently susceptible to OFX (MIC 2 mg/ml) (Table 3).
Transductants carrying N538T+T546M (B24 and B25) mutation
were susceptible to all FQs tested which is similar to clinical strain
MLB 265 (N538T+T546M). For both the clinical and recombi-
nant strains, the MIC of CIP increased four-fold but remained
below the critical concentration. Based on these results, the
T546M mutation does not play a synergistic role in FQ resistance,
and the N538T mutation does not confer resistance to any of the
FQ antibiotics tested. In contrast to this study, the N538T
mutation was previously identified in four clinical isolates resistant
to OFX, but these clinical isolates also harbored gyrA QRDR
mutations often associated with FQ resistance [22].
The E540D and E540V mutations were identified in OFX-
resistant isolates from Vietnam [22] and were included in this
study to assess their clinical relevance. The E540V mutation was
recently shown to greatly increase the CIP IC50 of the gyrase
complex using in vitro enzymatic assay [9]. The E540D transduc-
tants (B30 and B31) were susceptible to CIP, LVX and OFX but
resistant to MXF (MIC 2–4 mg/mL). In this study, the resistance
pattern of the E540V mutation was dependent on the genetic
background of the transductant strain. In H37Rv, the E540V
transductant (B32) was consistently susceptible to CIP but
conferred resistance to LVX and OFX and showed a low-level
resistance to MXF (Table 3). On the contrary, in the Erdman
background, E540V (B33) exhibited cross-resistance to all of the
FQs tested during one round of testing but was susceptible to
MXF upon repeat testing (Table 3).
Discussion
FQ resistance in M. tuberculosis has been attributed mostly to the
modification of the gyrA QRDR region with mutations at codon 90
and 94 most commonly associated with drug resistance [15,16,17].
Recent studies have identified mutations such as A74S and T80A
which are outside of the defined QRDR in clinical isolates alone or
in combination with other QRDR mutations, but the effect of
mutations outside the traditional QRDR region on FQ resistance
is not clear [5]. Although gyrB mutations in FQ-resistant M.
tuberculosis isolates have recently been reported
[4,21,22,23,24,25,28], these mutations need to be assessed
genetically to enhance our understanding of FQ resistance and
possibly improve the molecular testing of FQ-resistant strains.
To date, the best evidence of involvement of gyrB mutations in
FQ resistance was generated from the use of in vitro enzymatic IC50
measurements for various FQs toward purified gyrase containing
wild type or mutant forms of GyrA or GyrB [9,21,26,27]. Many
GyrB mutants exhibit higher IC50 values; however it is not known
how high the IC50 needs to be to confer resistance to FQs. It would
be difficult to standardize these assays to allow one to correlate the
IC50 with the exact MIC for each FQ. Additional evidence for the
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identification of gyrB mutations in phenotypically FQ-resistant
isolates [15,17]. However, it is often difficult to compare FQ-
resistant isolates from various studies due to the differences in
testing procedures (method and medium for drug susceptibility
testing (DST)) and the definitions of resistance. In many cases, the
FQ-resistant strains harbored not only gyrB mutations but also gyrA
mutations known to confer resistance and could also contain other
unidentified mutations [22,25].
To circumvent these concerns, we introduced specific mutations
into the chromosomal copy of either gyrA or gyrB of fully
susceptible M. tuberculosis strains using a specialized phage system
and determined the MIC for various FQs. A strain was considered
resistant to a FQ if the MIC was greater than the recommended
testing critical concentration by the proportion method suggested
by CLSI [36]. The allelic exchange system used in this study has
been successfully employed by Vilcheze et al [32] to transfer inhA
S94A mutation to M. tuberculosis and M. bovis BCG to unambig-
uously demonstrate that S94A indeed confers resistance to
isoniazid and ethionamide antibiotics. In addition, Starks et al
[42] used this same system to prove that embB codon 306 confers
ethambutol resistance in M. tuberculosis. One caveat to the phage
system is that the efficiency and preferred site of recombination
can vary between constructs. Additionally, the location of the
desired mutation within the allelic exchange substrate can also
affect the efficiency of its integration into the chromosome.
Fortunately, we were able to introduce the desired mutations into
multiple genetic backgrounds for most mutations analyzed in this
study. However, in a few cases, especially for gyrA, this proved
more difficult, and we were ultimately unable to introduce a small
number of mutations into one or the other background. We did
not experience this problem with the gyrB mutations probably due
to the amount of homologous DNA surrounding the mutations
which was much greater as compared to the gyrA mutations.
In this study, we identified two mutations, G247S and A384V,
located outside of the gyrA QRDR in FQ-susceptible and resistant
isolates. Neither mutation affected the MIC for any of the FQs
tested when transferred into a wild type background. These
mutations may be naturally occurring polymorphisms and do not
play any role in FQ resistance. In contrast to an earlier report [37],
the A74S mutation only slightly increased the MIC for OFX and
MXF instead of exhibiting high-level resistance. The discordance
between the studies could be due to different genetic backgrounds
of the strains, and the clinical strain in the earlier report could
possibly harbor additional mutations that also affect the MIC level.
The A74S mutation did act synergistically with the D94G
mutation and increase the MIC 2–8 fold over either mutation
alone. Neither the T80A nor A90G mutation conferred resistance
either alone or in combination. In fact, strains harboring the A90G
mutation were hypersusceptible to the FQs as demonstrated with
in vitro enzymatic assays [21]. Thus, with the exception of A74S/
D94G combination, mutations outside of the gyrA QRDR tested in
this study did not lead to FQ resistance.
The QRDR region of gyrA is well defined, and the majority of
mutations found in this region confer resistance to FQs, albeit not
at the same level (unpublished data). The same is not true for gyrB,
and recently it was proposed to expand the QRDR region of gyrB
to include amino acids 500–540 (Fig. 1) [27]. More than 15
mutations have been identified in this region alone and several
mutations have been identified that are located outside of the
QRDR of gyrB [40]. The list of gyrB mutations continues to grow
as more groups analyze gyrB of FQ-resistant isolates. Until now, no
functional genetic studies in M. tuberculosis were completed to
definitively determine if a specific mutation was able to confer
resistance as determined by standardized DST methods.
We analyzed 19 different mutations located either within or
outside of the gyrB QRDR to determine their role in FQ resistance.
The mutations located outside of the QRDR either had no effect
or only slightly increased the MIC levels for the FQs tested.
However, this increase was not sufficient to be considered resistant
by our testing method. The mutations located within the QRDR
of GyrB exhibited an array of MIC levels and conferred resistance
to various FQs. D533A was the only mutation located within the
QRDR of GyrB that did not exhibit any significant increase in the
MIC level for the four FQs. The double mutation, N538T +
T546M, was also not sufficient to confer resistance to any of the
FQs.
Several substitutions were analyzed at residues 500, 538, 539,
and 540 within the QRDR of GyrB, and different substitutions at
a single residue did not confer the same level or pattern of
resistance. For instance, the D500A mutation did not confer
resistance to any of the FQs tested while D500H and D500N
conferred resistance to OFX and LVX. The MIC for OFX and
LVX was 2 fold higher for these two mutations as compared to
D500A. Based upon the structural model of the M. tuberculosis
gyrase in complex with a nicked dsDNA substrate and a quinolone
in this and other studies [33,34], D500 lies in the quinolone
binding pocket (QBP) and the aliphatic part of this glutamate
residue likely interacts with the alkyl or cycloalkyl group at R1 of
the FQs (Fig. 2). The carboxyl group of D500 may be involved in
hydrogen bonding interactions with the nearby residues and the
DNA base that stacks onto the quinolone ring, fitting snugly
between the DNA and the drug. The small and nonpolar alanine
substitution of D500 would presumably be involved in a similar
interaction while being readily accommodating to substitutions as
large as a cyclopropyl at R1 of the FQs. In contrast, the larger side
chains of histidine and asparagine that bear a positive charge may
alter the geometry and electrostatics of the binding pocket and
disfavor FQ binding. These mutations conferred resistance to
LVX and OFX which have the same R1 group (the active form of
OFX is LVX) and did not confer resistance to MXF or CIP which
both have a cylcopropyl group at R1.
Residues 538–540 of GyrB form a part of the QBP and interact
with the R7 group of FQs. The N538D mutation is one of the
more common GyrB mutations found in FQ-resistant isolates [40].
In this study, this mutation conferred resistance to all four FQs
tested and increased the MIC levels greater than any other single
mutation in gyrB. The side chain amine of this asparagine appears
to make a hydrogen bond as a donor with the phosphoribose
moiety of the nucleotide that stacks with the quinolone ring. In
addition, this side chain can also interact sterically with the R7
group in case of a methyl piperazinyl or a comparable sized
substitution, fitting snugly between the drug and the DNA. The
mutation of this asparagine to an aspartic acid may remove the
electron donating character and introduce a rather unfavorable
electrostatic repulsion of the DNA backbone thus disfavoring the
quinolone binding and resulting in higher levels of resistance. The
lysine substitution at this position increased the MIC for all FQs
but was only resistant to MXF. The fold increase of the MIC for
MXF was greater than the other FQs. The longer side chain of a
lysine residue is not easily accommodated in this region, and since
the R7 group of MXF is much larger (azabicyclo) compared to the
piperazine and methylpiperazine of CIP, OFX and LVX, this may
explain why N538K is resistant only to MXF. A threonine at
position 538 (N538T) does not alter the electrostatics of the pocket
or its geometry as much as the other substitutions and does not
lead to resistance for the FQs tested. Based on our modeling and
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e39754Figure 2. A structural model of M. tuberculosis gyrase inhibition. A. A model of M. tuberculosis gyrase in complex with DNA and levofloxacin.
The model was built based on the crystal structure of the complex of Streptococcus pneumoniae (PDB ID: 3K9F) as described in Materials and
Methods. The GyrA subunit is shown in yellow, GyrB is in green, DNA is in orange, the levofloxacin molecule is shown as pink sticks. B. A zoomed-in
view of the quinolone binding site. Residues that directly interact with the quinolone and whose mutations cause resistance are shown by blue sticks.
The two residues whose double, but not single, mutations cause fluoroquinolone resistance are shown by red sticks.
doi:10.1371/journal.pone.0039754.g002
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of residue T539 points into the solvent; consistently, substitutions
at this position (T539N and T539P) did not reproducibly confer
resistance. The T539P mutation did confer low-level resistance to
MXF for one round of testing. The nonpolar character of the
solvent-exposed proline or the higher rigidity of the backbone
introduced by this substitution may be structurally perturbing to
the backbone, affecting the flanking residues (N538 and E540),
both of which interact directly with the drug.
The E540V mutation conferred resistance to all four FQs in this
study which was also reported for a clinical isolate with the same
mutation in recent studies [9,27]. This glutamate appears to
interact with the drug through hydrophobic interactions between
its aliphatic portion and a hydrophobic group at R7 (e.g the
methyl of the methyl piperazinyl) whereas the carboxylate likely
forms a salt bridge with R521 thereby positioning it for several
direct interactions with both DNA and the drug. The valine
substitution at this position likely perturbs this arginine coordina-
tion. These alterations are sufficient to confer resistance to
multiple classes of FQs. Interestingly, the substitution of glutamic
acid for aspartic acid (E540D) conferred high-level resistance to
MXF and did not significantly alter the MIC for the other three
FQs. This substitution may still accommodate the salt bridge with
the arginine and would only slightly shorten the side chain, likely
affecting interactions with R7. The aspartate residue seems to be
able to form hydrogen bonds with CIP, OFX, and LVX which
have very similar R7 groups (piperazine and methylpiperazine) but
not with the larger R7 group (azabicyclo) of MXF. In line with
these structural observations, the effect of the aspartate substitution
at this position is relatively subtle.
Mutations located outside of the QRDR of gyrB were not
capable of conferring resistance alone. However, we identified a
unique double mutation, R485C + T539N, with one mutation
located within and one outside of the QRDR that conferred
resistance to all four FQs, and the MIC levels were usually higher
than any single gyrB mutation. Based on structural modeling
(Fig. 2), the T539N mutation is located within the QBP as
described above. The R485C mutation is located at the GyrA-
GyrB interface and not near the quinolone binding site of the
gyrase complex. The arginine may be important for interactions
with GyrA to properly position GyrB relatively to DNA and thus
substitutions at this position could affect the quinolone binding
pocket allosterically. Together, these two mutations may destabi-
lize the QBP significantly enough to confer resistance. Based on
these data, the structural modeling appears to explain the results of
the MIC levels and resistance patterns observed for the GyrB
mutations investigated in this study.
Based on current literature, up to 58% of FQ-resistant M.
tuberculosis strains have no identified mutation in the QRDR region
of gyrA and possibly possess an alternate mechanism of resistance
[5,16,18,19,20]. Factors such as decreased cell wall permeability,
active efflux pumps, and drug sequestration or inactivation have
been proposed to account for FQ resistance in these isolates [19].
In a previous study, we sequenced the gyrA QRDR of 98 FQ-
resistant isolates and identified mutations within this region in
more than 80% of these isolates. The cause for FQ resistance in
the remaining isolates was unknown. Recent publications have
suggested a link between mutations within gyrB and FQ resistance,
and in the present study, we have generated gyrB mutations in well-
studied genetic backgrounds and demonstrated conclusively that
certain mutations within the GyrB QRDR do lead to FQ
resistance. Subsequently, we identified FQ-resistance conferring
gyrB mutations in several of the WT-gyrA isolates from our previous
study. During the course of the present study we came to
appreciate that the level of gyrA sequence heterogeneity among
specimens isolated from individuals is relatively high with many
individuals having both wild-type and mutant gyrA sequences.
Since, in our hands, Sanger sequencing can only detect sequences
that make up greater than 25–50% of the population we chose to
enrich for the resistant population in the remaining WT-GyrA,
WT-GyrB isolates by growing them on FQ containing media prior
to sequencing. Consequently, we identified mutations within gyrA
in all remaining isolates. Based on these results, we believe that the
majority, if not all, FQ resistance in M. tuberculosis can be attributed
to single nucleotide polymorphisms (SNPs) in gyrA and/or gyrB.
Importantly, several rapid molecular tests have been developed to
assess FQ resistance in M. tuberculosis utilizing mutations within the
GyrA QRDR as markers for FQ resistance [18,43,44], and based
on the current study, inclusion of the QRDR of gyrB in rapid
molecular testing which would detect specific substitutions in gyrB
and gyrA would provide a more complete picture of FQ resistance.
Unfortunately, FQ resistance imparted by GyrB QRDR muta-
tions seems to be more complex than is the case for GyrA
mutations, and the genetic background appears to have some
effect on resistance. Molecular assays that analyze the QRDR
region of gyrB need to determine the exact mutation since not all
mutations confer resistance and the pattern of cross-resistance
varies among the mutations.
Most laboratories performing DST for M. tuberculosis only test at
the critical concentration recommended for their specific testing
method. Strains harboring mutations leading to a higher MIC
level than wild-type strains but equal to or slightly less than the
critical concentration would test susceptible with conventional
testing. Data presented in this study demonstrates that this would
be the case for many of the gyrB mutations. Unfortunately, the
importance of these mutations in patient care is unknown. Clinical
evidence establishing the efficacy of treatment of individuals
infected with strains harboring these types of mutations with
various FQ is lacking. However, molecular assays could identify
these mutations that result in borderline resistance levels and alert
clinicians to possible treatment complications, and in some cases,
the genetic information could be useful in tailoring the treatment
regimen for the patient.
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